The endocannabinoid system: Overview of an emerging multi-faceted therapeutic target

Dipanjan Chanda; Dietbert Neumann; Jan F. C. Glatz

doi:10.1016/j.plefa.2018.11.016

The endocannabinoid system: Overview of an emerging multi-faceted therapeutic target

Dipanjan Chanda, Dietbert Neumann, Jan F. C. Glatz^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

346 Downloads (Pure)

Abstract

The endocannabinoids anandamide (AEA) and 2-arachidonoylglyerol (2-AG) are endogenous lipid mediators that exert protective roles in pathophysiological conditions, including cardiovascular diseases. In this brief review, we provide a conceptual framework linking endocannabinoid signaling to the control of the cellular and molecular hallmarks, and categorize the key components of endocannabinoid signaling that may serve as targets for novel therapeutics. The emerging picture not only reinforces endocannabinoids as potent regulators of cellular metabolism but also reveals that endocannabinoid signaling is mechanistically more complex and diverse than originally thought.

Original language	English
Pages (from-to)	51-56
Number of pages	6
Journal	Prostaglandins Leukotrienes and Essential Fatty Acids
Volume	140
DOIs	https://doi.org/10.1016/j.plefa.2018.11.016
Publication status	Published - Jan 2019

Keywords

2-arachidonoylglyerol
Anandamide
Insulin resistance
Ccardiovascular disease
CB2 CANNABINOID RECEPTORS
PHARMACOLOGICAL STRATEGIES
SPECIES-DIFFERENCES
RISK-FACTORS
RIMONABANT
PAIN
IDENTIFICATION
HYPOTHALAMUS
MODULATION
OVERWEIGHT

Access to Document

10.1016/j.plefa.2018.11.016

Full TextFinal published version, 410 KBLicence: Taverne

Cite this

@article{6fa28b29e9eb42ec94d8634b0012f59a,

title = "The endocannabinoid system: Overview of an emerging multi-faceted therapeutic target",

abstract = "The endocannabinoids anandamide (AEA) and 2-arachidonoylglyerol (2-AG) are endogenous lipid mediators that exert protective roles in pathophysiological conditions, including cardiovascular diseases. In this brief review, we provide a conceptual framework linking endocannabinoid signaling to the control of the cellular and molecular hallmarks, and categorize the key components of endocannabinoid signaling that may serve as targets for novel therapeutics. The emerging picture not only reinforces endocannabinoids as potent regulators of cellular metabolism but also reveals that endocannabinoid signaling is mechanistically more complex and diverse than originally thought.",

keywords = "2-arachidonoylglyerol, Anandamide, Insulin resistance, Ccardiovascular disease, CB2 CANNABINOID RECEPTORS, PHARMACOLOGICAL STRATEGIES, SPECIES-DIFFERENCES, RISK-FACTORS, RIMONABANT, PAIN, IDENTIFICATION, HYPOTHALAMUS, MODULATION, OVERWEIGHT",

author = "Dipanjan Chanda and Dietbert Neumann and Glatz, {Jan F. C.}",

note = "Funding Information: This study was supported by a Marie Curie Individual Incoming Fellowship to DC ( PIIF-GA-2012-332230 ). Publisher Copyright: {\textcopyright} 2018 Elsevier Ltd",

year = "2019",

month = jan,

doi = "10.1016/j.plefa.2018.11.016",

language = "English",

volume = "140",

pages = "51--56",

journal = "Prostaglandins Leukotrienes and Essential Fatty Acids",

issn = "0952-3278",

publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - The endocannabinoid system

T2 - Overview of an emerging multi-faceted therapeutic target

AU - Chanda, Dipanjan

AU - Neumann, Dietbert

AU - Glatz, Jan F. C.

PY - 2019/1

Y1 - 2019/1

N2 - The endocannabinoids anandamide (AEA) and 2-arachidonoylglyerol (2-AG) are endogenous lipid mediators that exert protective roles in pathophysiological conditions, including cardiovascular diseases. In this brief review, we provide a conceptual framework linking endocannabinoid signaling to the control of the cellular and molecular hallmarks, and categorize the key components of endocannabinoid signaling that may serve as targets for novel therapeutics. The emerging picture not only reinforces endocannabinoids as potent regulators of cellular metabolism but also reveals that endocannabinoid signaling is mechanistically more complex and diverse than originally thought.

AB - The endocannabinoids anandamide (AEA) and 2-arachidonoylglyerol (2-AG) are endogenous lipid mediators that exert protective roles in pathophysiological conditions, including cardiovascular diseases. In this brief review, we provide a conceptual framework linking endocannabinoid signaling to the control of the cellular and molecular hallmarks, and categorize the key components of endocannabinoid signaling that may serve as targets for novel therapeutics. The emerging picture not only reinforces endocannabinoids as potent regulators of cellular metabolism but also reveals that endocannabinoid signaling is mechanistically more complex and diverse than originally thought.

KW - 2-arachidonoylglyerol

KW - Anandamide

KW - Insulin resistance

KW - Ccardiovascular disease

KW - CB2 CANNABINOID RECEPTORS

KW - PHARMACOLOGICAL STRATEGIES

KW - SPECIES-DIFFERENCES

KW - RISK-FACTORS

KW - RIMONABANT

KW - PAIN

KW - IDENTIFICATION

KW - HYPOTHALAMUS

KW - MODULATION

KW - OVERWEIGHT

U2 - 10.1016/j.plefa.2018.11.016

DO - 10.1016/j.plefa.2018.11.016

M3 - Article

C2 - 30553404

SN - 0952-3278

VL - 140

SP - 51

EP - 56

JO - Prostaglandins Leukotrienes and Essential Fatty Acids

JF - Prostaglandins Leukotrienes and Essential Fatty Acids

ER -

The endocannabinoid system: Overview of an emerging multi-faceted therapeutic target

Abstract

Keywords

Access to Document

Fingerprint

Cite this